InterCure Ltd. Share Price TEL AVIV STOCK EXCHANGE

INCR

IL0011063760

Healthcare Facilities & Services

News in other languages: InterCure Ltd.

02/20/02

Tilray, Inc. : première exportation de cannabis vers Israël

More news

Managers and Directors: InterCure Ltd.

Manager	Title	Age	Since
Alexander Rabinovitch CEO	Chief Executive Officer	55	24/12/2019
Amos Cohen DFI	Director of Finance/CFO	47	01/03/2020
Itai Kabiljo LAW	General Counsel	-	01/04/2022

Director	Title	Age	Since
Lennie Michelson Grinbaum BRD	Director/Board Member	50	03/09/2015
David Salton BRD	Director/Board Member	66	14/12/2014
Alexander Rabinovitch CHM	Chairman	55	13/02/2025

More insiders

InterCure Ltd is an Israel-based company primarily enagged in cannabis industry. Thorugh its wholly owned subsidiary Canndoc the Company operates as licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products.

Employees

Sector

Healthcare Facilities & Services

More about the company

Market Cap	18Cr 53Cr 16Cr 14Cr 13Cr 25Cr 1.69TCr 26Cr 171.35Cr 67Cr 831.5Cr 67Cr 65Cr 2.87TCr	P/E 2024	-4.01x	P/E 2025	-4.87x
Enterprise Value	31Cr 94Cr 27Cr 25Cr 24Cr 45Cr 2.99TCr 45Cr 302.85Cr 117.73Cr 1.47TCr 117.86Cr 115.33Cr 5.06TCr	EV / Sales 2024	1.69x	EV / Sales 2025	1.16x
Free-Float	75.95%	Yield 2024 *	-	Yield 2025	-

22/06	InterCure Ltd. announced that it expects to receive ILS 21.711643 million in funding from Bennu Pharma Fund Ltd and other investors.	CI
15/06	InterCure Starts Review of US Medical Cannabis Opportunities; Completes Initial Closing of Botanico Acquisition	MT
15/06	InterCure Ltd. acquired 50% stake of Botanico Ltd.	CI
15/06	InterCure Ltd. completed the acquisition of 50% stake in Botanico Ltd.	CI
01/05	InterCure Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
04/03	InterCure Receives Noncompliance Notice From Nasdaq	MT
04/03	InterCure receives Nasdaq notification regarding minimum bid requirement	RE
19/02	InterCure announces preliminary estimated 2025 revenue of NIS 265 million, positive adjusted EBITDA and cash of NIS 43 million	RE
19/12	InterCure Ltd on Dec 15, became aware that Bazelet Group of Companies has initiated Restructuring proceedings before the Israeli district court	RE
03/11	Cannasoul Analytics Ltd. announced that it expects to receive funding from InterCure Ltd.	CI
03/11	InterCure Ltd. Enters into A Collaboration Agreement with Cannasoul R&D Ltd	CI
08/25/08	InterCure Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
08/25/08	Intercure reports first half 2025 results with NIS 130 million in revenue and positive operating cash flow	RE

22/06	InterCure Secures NIS 22 Million in Private Placement Financing Led by Leading Pharma-Focused Hedge Funds	AQ
15/06	InterCure Initiates Strategic Review of U.S. Medical Cannabis Opportunities Following Historic Federal Rescheduling and Completes the Initial closing of Botanico Acquisition	AQ
01/05	InterCure Announces 2025 Results with NIS 270 Million in Revenue and Positive Operating Cash Flow	AQ
04/03	InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement	AQ
19/02	InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million	AQ

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
INTERCURE LTD.	+0.22%	-0.51%	-	-	5.98Cr
CORDYCEPS SUNSHINE BIOTECH HOLDINGS CO., LTD.	+72.76%	-.--%	-39.25%	-	58Cr
VILLAGE FARMS INTERNATIONAL, INC.	-2.01%	+3.17%	+53.54%	+205.98%	22Cr
ORGANIGRAM GLOBAL INC.	0.00%	-0.68%	-24.08%	-27.50%	14Cr
CANNARA BIOTECH INC.	0.00%	+8.93%	+22.00%	+103.33%	13Cr
ASCEND WELLNESS HOLDINGS, INC.	0.00%	-6.00%	+46.88%	-24.19%	9.54Cr
JUSHI HOLDINGS INC.	+4.47%	-4.14%	+45.28%	-2.60%	9.28Cr
Average	+10.78%	+4.69%	+17.39%	+51.00%	21Cr
Weighted average by Cap.	+31.83%	+3.36%	-2.17%	+77.03%

	2024	2025
Net sales	24Cr 72Cr 21Cr 19Cr 18Cr 34Cr 2.27TCr 34Cr 230.36Cr 90Cr 1.12TCr 90Cr 88Cr 3.85TCr	27Cr 81Cr 24Cr 22Cr 20Cr 38Cr 2.57TCr 39Cr 260.6Cr 101.31Cr 1.26TCr 101.42Cr 99Cr 4.36TCr
Net income	-6.78Cr -20Cr -5.93Cr -5.45Cr -5.08Cr -9.63Cr -645.5Cr -9.78Cr -65Cr -25Cr -317.3Cr -25Cr -25Cr -1.09TCr	-3.57Cr -11Cr -3.12Cr -2.87Cr -2.67Cr -5.07Cr -340.01Cr -5.15Cr -34Cr -13Cr -167.13Cr -13Cr -13Cr -575.93Cr
Net Debt	13Cr 40Cr 12Cr 11Cr 9.94Cr 19Cr 1.26TCr 19Cr 128.04Cr 50Cr 621.32Cr 50Cr 49Cr 2.14TCr	14Cr 41Cr 12Cr 11Cr 10Cr 19Cr 1.3TCr 20Cr 131.5Cr 51Cr 638.1Cr 51Cr 50Cr 2.2TCr

InterCure Ltd. Share Price TEL AVIV STOCK EXCHANGE

Stocks

INCR

IL0011063760

Healthcare Facilities & Services

Valuation: InterCure Ltd.

Latest news : InterCure Ltd.

Press Releases: InterCure Ltd.

News in other languages: InterCure Ltd.

Quotes and Performance

Managers and Directors: InterCure Ltd.

Medical Farming

Financials

Company Profile